About Us: Relburn is a team of smart, dedicated and high-energy individuals who appreciate a challenging entrepreneurial environment and who contribute daily to our company objectives. We are committed to aggressively leveraging our expertise in metabolic drug discovery, development, and commercialization.
Our Mission: Relburn is a biopharmaceutical company focused on the identification, development and commercialization of metabolic drugs. Our strategy is to maximize value through excellence in performance and innovation, while maintaining the highest standards of integrity and leadership. Relburn is committed to developing innovative products to better the lives of people with chronic disorders of metabolism. The Company’s lead program is in chronic gout and inflammation.
About Metabolomics: “Chronic human illness commonly results from dysfunction in multiple physiologic pathways, and discovery strategies based on concepts of “one-target, one-disease” are proving increasingly unsuccessful. Metabolomics has driven an interest in agents that modulate multiple targets simultaneously. Targeting cellular function as a system, rather than at a single-target, may lead to novel classes of effective multi-targeted drugs with fewer side-effects.”*
Following this principle, Relburn uses a single small molecule to inhibit multiple targets in a metabolic pathway that leads to gout. These metabolic targets affect both sides of an equilibrium that simultaneously reduces production as well as enhances excretion of uric acid, the proximal cause of gout.
*Paragraph adapted from Schrattenholz A, et al: Methods Mol Biol. 662:29-58, 2010.